India on 14 May 2013 unveiled its indigenously developed Rotavirus Vaccine named Rotavac after the Phase-III clinical trial of low cost rotavirus Vaccine. The Rotavac that has demonstrated strong efficacy and excellent safety profile; if gets its approval by the Drugs Controller General of India (DCGI) than will be made available in the market at a rate of 54 rupees per dose.
Approx 453000 child across the world dies every year due to Rotavirus diarrhea and following the recent reports every year approx one lakh children below five years in India die due to severe diarrhea that is caused due to Rotavirus bacteria. India accounts for 22 percent of the global deaths that occurs due to diarrhoea-causing rotavirus.
Rotavac vaccine has been developed under a public-private partnership and is the third such vaccine that will hit the Indian market. The previous two vaccines cost more than 1000 rupees per dose and thus remain out of reach from the hands of millions in developing and third world nations.
It is an oral vaccine that is administered in infants in three dose course at ages of six, ten and fourteen weeks, which is given to a child along with the Universal Immunisation Programme (UIP) vaccines recommended to be given to children.
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.